TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Merck & Company (MRK)

NYSE:MRK

Merck & Company (MRK)

130.20
+0.41 (0.32%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
311 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Merck & Company (MRK) is recognized for its strong performance, particularly bolstered by its cancer treatment drug, Keytruda, which is a significant revenue driver but faces a looming patent cliff. Despite concerns regarding the future of Keytruda, many experts are optimistic about the company's robust drug pipeline and strategic acquisitions that should help mitigate the risks associated with the loss of this key drug. The consensus among analysts suggests solid revenue growth potential, with expectations that the company will release a considerable number of new drugs by 2030. Additionally, Merck is committed to returning capital to shareholders, which includes stock buybacks and steady dividends, positioning the company as a quality investment in the healthcare sector.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Pfizer, PFE
BUY

Merck & Company(MRK)

Nov 06, 2003
Missed its numbers. Demographics for drugs looks great. At a great price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$43.60

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Sep 03, 2003
Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$50.68

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Aug 05, 2003
Trading at a significant discount.Has been getting left behind.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$53.51

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Merck & Company(MRK)

Jul 23, 2003
(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$57.89

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Jun 02, 2003
2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$55.73

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

May 21, 2003
Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.
Photo of Laura WallaceLaura WallaceUnlock Rating
$55.38

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Mar 24, 2003
Good price. Good earnings price momentum.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$54.65

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Feb 04, 2003
Health care sector is a good sector. 15/16 PE. Good price.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$54.85

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
WEAK BUY

Merck & Company(MRK)

Jan 02, 2003
Some of their drugs have come off patent and they are having difficulty with Research /Development productivity. Prefers Pfizer.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$58.25

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Oct 02, 2002
Pharmaceuticals look good in any upturn. 3% dividend. Trading at 15 X earnings. Had no earnings growth this year.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$46.95

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Sep 25, 2002
Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.
Photo of Laura WallaceLaura WallaceUnlock Rating
$47.70

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Sep 04, 2002
Likes the valuations. Good balance sheet and good earnings.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$49.13

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Aug 20, 2002
Outlook for drug companies is good. A bit expensve, but long term is good.
Photo of Ray SteeleRay SteeleUnlock Rating
$50.64

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jun 06, 2002
Sector has been hit hard. At a good level. Prefers Pfizer.
Photo of John ZechnerJohn ZechnerUnlock Rating
$53.20

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Merck & Company(MRK)

May 09, 2002
(Was a top pick on Apr 4 up 1.5%) Still likes.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$55.76

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 271 to 285 of 307 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like